🔴 LIVE: The Secrets of ProPicks AI Success Revealed + November’s List FREEWatch Now

Puma Biotechnology Inc (PBYI)

NASDAQ
Currency in USD
3.175
-0.125(-3.79%)
Real-time Data
PBYI Scorecard
Full Analysis
High shareholder yield
Fair Value
Day's Range
3.0653.370
52 wk Range
2.2257.730
Key Statistics
Edit
Prev. Close
3.3
Open
3.32
Day's Range
3.065-3.37
52 wk Range
2.225-7.73
Volume
612,603
Average Volume (3m)
348,219
1-Year Change
-5.71%
Book Value / Share
unlockUnlock
Fair Value
unlockUnlock
Fair Value Upside
unlockUnlock
PBYI Scorecardpro icon
Company’s Health
pro lockUnlock
Fair Value
pro lockUnlock Price
Fair Pricepro lock
Upsidepro lock
Price Target
4.333
Upside
+36.472%
Members' Sentiments
Bearish
Bullish
ProTips
RSI suggests the stock is in overbought territory
Show more

Puma Biotech Company Profile

Puma Biotechnology, Inc., a biopharmaceutical company, focuses on the development and commercialization of products to enhance cancer care in the United States and internationally. The company offers NERLYNX, an oral version of neratinib that is used to treat adult patients with early stage HER2-overexpressed/amplified breast cancer; and advanced or metastatic HER2-positive breast cancer when combined with capecitabine. It also develops alisertib, a small molecule inhibitor of aurora kinase A for the treatment of hormone receptor positive breast cancer, triple negative breast cancer, small cell lung cancer, and head and neck cancer. The company sells its products through specialty pharmacy and distributor networks. It has license agreements with Pfizer Inc. for the development, manufacture, and commercialization of neratinib (oral), neratinib (intravenous), PB357, and related compounds; and Takeda Pharmaceutical Company Limited for the research, development, and commercialization of alisertib, as well as sub-license agreements with Specialised Therapeutics Asia Pte Ltd., Medison Pharma Ltd., Pint Pharma International SA, Knight Therapeutics, Inc., Pierre Fabre Medicament SAS, and Bixink Therapeutics Co., Ltd. The company was founded in 2010 and is headquartered in Los Angeles, California.

Compare PBYI to Peers and Sector

Metrics to compare
PBYI
Peers
Sector
Relationship
P/E Ratio
6.7x−1.8x−0.6x
PEG Ratio
0.01−0.030.00
Price/Book
2.2x1.8x2.6x
Price / LTM Sales
0.6x2.0x3.2x
Upside (Analyst Target)
21.2%65.7%43.6%
Fair Value Upside
Unlock30.7%5.8%Unlock

FAQ

What Is the Puma Biotech (PBYI) Stock Price Today?

The Puma Biotech stock price today is 3.175.

What Stock Exchange Does Puma Biotech Trade On?

Puma Biotech is listed and trades on the NASDAQ stock exchange.

What Is the Stock Symbol for Puma Biotech?

The stock symbol for Puma Biotech is "PBYI."

What Is the Puma Biotech Market Cap?

As of today, Puma Biotech market cap is 150.94M.

What is Puma Biotech Earnings Per Share?

The Puma Biotech EPS is 0.481.

What Is the Next Puma Biotech Earnings Date?

Puma Biotech will release its next earnings report on 26 Feb 2025.

From a Technical Analysis Perspective, Is PBYI a Buy or Sell?

Based on moving averages and other technical indicators, the daily buy/sell signal is Strong Buy.
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2024 - Fusion Media Limited. All Rights Reserved.